SCHEMBL4455191

SCHEMBL4455191

COc1cccc(Cn2ncc3c(-c4cc[nH]n4)nc(N)nc32)c1

nearest known ligand 0.67

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 18/20 0.67
ADORA1 P30542 12/20 0.67
ADORA2B P29275 2/20 0.48
ADORA3 P0DMS8 1/20 0.48
HDAC1 Q13547 6/20 0.46
HDAC3 O15379 1/20 0.45
HDAC2 Q92769 1/20 0.45
HDAC8 Q9BY41 1/20 0.45
HDAC6 Q9UBN7 1/20 0.45
AURKA O14965 1/20 0.44
GRK2 P25098 1/20 0.44
ROCK1 Q13464 1/20 0.44
RPS6KA1 Q15418 1/20 0.44
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4454673 0.88 ADORA2A (0.63) ADORA2AADORA1ADORA2BADORA3HDAC1
SCHEMBL4457050 0.84 ADORA2A (0.67) ADORA2AADORA1ADORA2BADORA3HDAC1
SCHEMBL13601287 0.82 ADORA2A (0.66) ADORA2AADORA1ADORA2BADORA3HDAC1
SCHEMBL4453248 0.81 ADORA2A (0.48) ADORA2AADORA1HDAC1MEN1KMT2A
SCHEMBL4456961 0.80 ADORA2A (1.00) ADORA2AADORA1ADORA2BADORA3HDAC1
SCHEMBL4455658 0.80 ADORA2A (0.67) ADORA2AADORA1ADORA2BADORA3HDAC1
SCHEMBL4455173 0.76 ADORA2A (0.70) ADORA2AADORA1ADORA2BADORA3
SCHEMBL13601214 0.71 ADORA2A (0.84) ADORA2AADORA1ADORA2BHDAC1HDAC3
SCHEMBL4455479 0.71 ADORA2A (0.65) ADORA2AADORA1ADORA2BADORA3HDAC1
SCHEMBL25301075 0.69 KMT2A (0.54) ADORA2AADORA1AURKAGRK2ROCK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7629349-B2 Pyrazolo [3,4-d] pyrimidine derivatives and their use as purinergic receptor antagonists VERNALIS RESEARCH LIMITED (GB) 2009-12-08 US claimed
US-7087754-B2 Pyrazolo[3,4-d]pyrimidine derivatives and their use as purinergic receptor antagonists VERNALIS RESEARCH LIMITED (GB) 2006-08-08 US claimed
US-20060111373-A1 PYRAZOLO [3,4-D] PYRIMIDINE DERIVATIVES AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS VERNALIS RESEARCH LIMITED 2006-05-25 US claimed
US-7629349-B2 Pyrazolo [3,4-d] pyrimidine derivatives and their use as purinergic receptor antagonists VERNALIS RESEARCH LIMITED (GB) 2009-12-08 US disclosed
EP-1349552-B1 PYRAZOLO[3,4-d]PYRIMIDINE DERIVATIVES AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS VERNALIS RES LTD (GB) 2008-08-20 EP disclosed
US-7087754-B2 Pyrazolo[3,4-d]pyrimidine derivatives and their use as purinergic receptor antagonists VERNALIS RESEARCH LIMITED (GB) 2006-08-08 US disclosed
US-20060111373-A1 PYRAZOLO [3,4-D] PYRIMIDINE DERIVATIVES AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS VERNALIS RESEARCH LIMITED 2006-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060111373-A1 PYRAZOLO [3,4-D] PYRIMIDINE DERIVATIVES AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS CHRNA6, CHRNA5, CNR1 ADORA2A 6/4885ADORA1 15/4885ADORA2B 36/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.